Tango Therapeutics, Inc. (TNGX) Operating cash flow 2020–2025
Tango Therapeutics, Inc. (TNGX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$138.9MFY2025 · since FY2020: $70.1M → -$138.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$138.9M | -5.6% |
| FY2024 | -$131.5M | -11.5% |
| FY2023 | -$118.0M | -8.2% |
| FY2022 | -$109.1M | -83.2% |
| FY2021 | -$59.5M | -184.9% |
| FY2020 | $70.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TNGX financial trends
TNGX RevenueTNGX Net incomeTNGX Net marginTNGX Gross profitTNGX Gross marginTNGX Operating incomeTNGX Operating marginTNGX Free cash flowTNGX Capital expendituresTNGX Return on equityTNGX Stock buybacksTNGX Dividends paidTNGX Total assetsTNGX Total liabilitiesTNGX Shareholders’ equityTNGX overview →